SCHEMBL3213574

SCHEMBL3213574

C[N+]1(C)CC2CCC(C1)C2COC(=O)C(O)(c1ccccc1)C1CCCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 6/20 0.58
CHRM2 P08172 5/20 0.58
CHRM1 P11229 4/20 0.57
KCNH2 Q12809 4/20 0.57
CHRM4 P08173 2/20 0.57
CHRM5 P08912 2/20 0.57
HTR2B P41595 2/20 0.57
HRH1 P35367 2/20 0.57
POLB P06746 1/20 0.57
ALDH1A1 P00352 1/20 0.57
CYP2C19 P33261 2/20 0.56
SLC6A3 Q01959 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
PKM P14618 1/20 0.56
NFKB1 P19838 1/20 0.56
THPO P40225 1/20 0.56
ABCB11 O95342 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3226729 1.00 CHRM3 (0.58) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3224624 0.90 POLB (0.52) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3224057 0.90 POLB (0.52) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3219807 0.86 CHRM2 (0.46) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3201448 0.85 ALDH1A1 (0.56) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3222102 0.85 ALDH1A1 (0.56) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3210018 0.83 CHRM2 (0.48) CHRM3CHRM2CHRM1
SCHEMBL3226674 0.83 CHRM2 (0.48) CHRM3CHRM2CHRM1
SCHEMBL17553423 0.83 CHRM3 (0.66) CHRM3CHRM2CHRM1KCNH2CHRM4
SCHEMBL3222150 0.81 HTT (0.53) CHRM3CHRM2CHRM1KCNH2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US claimed
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2010-03-04 US disclosed
EP-2059505-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2009-05-20 EP disclosed
WO-2008029349-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056496-A1 MUSCARINIC RECEPTOR ANTAGONISTS CHRM3, CHRM5, CHRM2 CHRM3 1/4885CHRM2 3/4885CHRM1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.